Assembly BiosciencesASMB -1.69%31 EV-to-OCF is -8.02 as of Jul. 11, 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Assembly Biosciences ranks better than 65.65% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Assembly Biosciences's Enterprise Value is $318.88 Mil.
Assembly Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.75 Mil. Therefore, Assembly Biosciences's EV-to-OCF for today is -8.02.
The historical rank and industry rank for Assembly Biosciences's EV-to-OCF or its related term are showing as below:
ASMB'
s EV-to-OCF Range Over the Past 10 Years
Min: -17.58 Med: -0.06 Max: 1304.71
Current: -8.02
During the past 13 years, the highest EV-to-OCF of Assembly Biosciences was 1304.71. The lowest was -17.58. And the median was -0.06.
ASMB's EV-to-OCF is ranked better than 65.65% of 1409
companies
in the Biotechnology industry
Industry Median: -3.52
vs ASMB: -8.02
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Assembly Biosciences's PE Ratio (TTM) for today is calculated as:
Assembly Biosciences's share price for today is $27.42.
Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.197.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Assembly Biosciences EV-to-OCF Related Terms
Assembly Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Assembly Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's EV-to-OCF falls into.
Assembly Biosciences's current Enterprise Value is $318.88 Mil.
Assembly Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a EV-to-OCF of -8.02 as of Jul. 11, 2026. According to the industry distribution chart, Assembly Biosciences ranks #484 out of 1409 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Assembly Biosciences' EV-to-OCF too high?
Assembly Biosciences' current EV-to-OCF is -8.02. Based on the distribution chart, Assembly Biosciences ranks #484 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' EV-to-OCF compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #484 out of 1409 companies for EV-to-OCF. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Assembly Biosciences's current EV-to-OCF is -8.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current EV-to-OCF of -8.02. The current EV-to-OCF is -8.02. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current EV-to-OCF is -8.02 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score
Get the complete analysis for ASMB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
